The contract research organization, Charles River Laboratories International, Inc., has agreed to acquire Celsis International Ltd. for $212 million in cash, subject to customary closing adjustments. Celsis is a provider of rapid bacterial detection systems for quality control testing for biopharmaceutical manufacturing.

The acquisition complements Charles River’s endotoxin and microbial detection's (EMD) services for rapid endotoxin testing and bacterial identification for biopharmaceutical manufacturing. With the addition of Celsis, Charles River will gain Celsis’ Advance II, Accel, and Innovate systems for non-sterile applicationsto complement Charles River’s recently introduced PTS-Micro, a rapid bacterial (bioburden) detection system for sterile biopharmaceutical applications. The transaction is expected to close in the third quarter of 2015, subject to customary closing conditions.

Source: Charles River Laboratories